

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI388553

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	Tonix Pharmaceuticals Holding Corp.	07/25/2024
RECEIVING PARTY DATA		
Company Name:	Tonix Pharma Limited	
Street Address:	3 Marine Road, Dun Laoghaire	
City:	Dublin	
State/Country:	IRELAND	
Postal Code:	A96 HW25	
PROPERTY NUMBERS Total: 6		
Property Type	Number	
Application Number:	61228946	
Application Number:	12844721	
Application Number:	13802075	
Application Number:	62637187	
Application Number:	16976912	
Application Number:	18621985	
CORRESPONDENCE DATA		
Fax Number:	6462196229	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(646)973-2525	
Email:	carolina.rodriguez@hglaw.com	
Correspondent Name:	Haley Guiliano LLP	
Address Line 1:	75 Broad Street	
Address Line 2:	Suite 1000	
Address Line 4:	New York, NEW YORK 10004	
ATTORNEY DOCKET NUMBER:	104545-0066/68	
NAME OF SUBMITTER:	Carolina Rodriguez	
SIGNATURE:	Carolina Rodriguez	
DATE SIGNED:	07/26/2024	

Total Attachments: 5

source=104545-0066-0068-Assignment#page1.tiff

source=104545-0066-0068-Assignment#page2.tiff

source=104545-0066-0068-Assignment#page3.tiff

source=104545-0066-0068-Assignment#page4.tiff

source=104545-0066-0068-Assignment#page5.tiff

ASSIGNMENT

WHEREAS, **TONIX PHARMACEUTICALS HOLDING CORP.**, a corporation organized and existing under the laws of the State of Nevada, and having an office and a place of business at 26 Main Street, Suite 101, Chatham, NJ 07928, United States of America, (hereafter the "Assignor"), is the owner by respective Assignment of the following patent applications and their rights of priority, and had assigned, sold, and transferred the entire right, title and interest in and to all of the patent applications and patents identified in Schedule A appended to this Assignment and any patent to be issued thereon, to **TONIX PHARMA LIMITED.**, a private company limited by shares organized and existing under the laws of the Republic of Ireland, and having an office and a place of business at 3 Marine Road, Dun Laoghaire, Dublin, A96 HW25, Ireland (hereinafter the "Assignee").

NOW, THEREFORE, in consideration of said agreements and of other good and valuable consideration, including the sum of 1.00 USD, the receipt of which is hereby acknowledged, Assignor confirms that Assignor has sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said Assignee, their successors, assigns and legal representatives, Assignor's entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said Applications (and any and all of invention(s) described therein) and all patent applications that may be filed claiming the benefit to and/or priority to those Applications, including any continuation, continuation-in-part, divisional, International Patent Applications, and foreign counterparts thereof and any substitute applications therefor, and any patents as may issue thereon, or resulting from the national or regional phase of the above-identified International Patent Application in any country of the world, and any reissues and revivals of the same (together with Applications "Applications and Patents") and including the right to claim priority under any applicable statute, treaty or convention based on said Applications or invention(s) therein; said invention(s), right of priority, Applications and Patents to be held and enjoyed by said Assignee for its own use and for that of its successors, assigns and legal representatives, to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held by Assignor had this assignment not been made. Assignor also hereby conveys all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing such

applications, all choses in action pertaining to the Applications and Patents including the right to sue for and collect damages and other recoveries for past infringement thereof, all rights to initiate proceedings before government and administrative bodies, and all files, records and other materials arising from the prosecution, exploitation, or defense of rights and registrations pertaining to the applications and patents. Assignor hereby acknowledges that this assignment, being of Assignor's entire right, title and interest in and to said invention(s), Applications and Patents, carries with it the right in Assignee to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of Assignee's selection and the right to procure the grant of all such patents to Assignee for its own name as Assignee of Assignor's entire right, title and interest therein;

AND, Assignor hereby further agrees for itself and its executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid right of priority, invention(s), Applications and Patents to said Assignee, its successors, assigns and legal representatives, including the execution of applications for patents of the United States and all foreign countries, and the execution of substitute, reissue, divisional, continuation or continuation-in-part applications and preliminary or other statements and the giving of testimony in any interference, derivation or other proceeding in which said invention(s) or the Applications and/or Patents may be involved;

AND, Assignor does hereby authorize and request the Commissioner of Patents of the United States and the respective patent offices in all foreign countries to issue such patents as shall be granted upon said Applications or Applications and Patents based thereon or claiming right to priority thereto, to said Assignee, its successors, assigns, and legal representatives.

IN WITNESS WHEREOF, executed by the Assignor's undersigned representative on the date following the undersigned's name.

TONIX PHARMACEUTICALS HOLDING CORP.

By:  Date: 7/25/24

Name: Bradley Saenger
Title: Chief Financial Officer

On this 25 day of JULY, 2024,
Bradley Saenger personally appeared before me, a Notary
Public in and for Westchester County,
the State of New York, and executed this
Assignment.

(Seal)


Signature: 

AHN TED TAESHIK
Notary Public, State of New York
No. 01AN6286995
Qualified in Westchester County
Commission Expires 08/05/2025

ACKNOWLEDGEMENT OF ASSIGNEE:

I hereby acknowledge the foregoing executed Assignment on behalf of **TONIX PHARMA LIMITED.**

By:


Name: Bradley Saenger
Title: Director

Date:

7/25/24

On this 25 day of JULY, 2024,
Bradley Saenger personally appeared before me, a Notary
Public in and for Westchester County,
the State of New York, and executed this
Assignment.

(Seal)

AHN TED TAESHIK
Notary Public, State of New York
No. 01AN6286995
Qualified in Westchester County
Commission Expires 08/05/2025

Signature:



Schedule A – Tonix Pharmaceuticals Holding Corp. to Tonix Pharma Limited Assignment

Country	Status	Application #	Date Filed	Patent #	Grant Date
United States of America	Expired	62/637,187	Mar 1, 2018		
United States of America	Issued	16/976,912	Aug 31, 2020	11,970,554	Apr 30, 2024
United States of America	Pending	18/621,985	Mar 29, 2024		
European Patent Office	Pending	19710979.6	Mar 1, 2019		
Japan	Pending	2020-545532	Mar 1, 2019		
Japan	Pending	2024-009405	Mar 1, 2019		
PCT	Closed	PCT/US2019/020419	Mar 1, 2019		
United States of America	Expired	61/228,946	July 27, 2009		
United States of America	Issued	12/844,721	July 27, 2010	8,551,949	Oct 8, 2013
United States of America	Issued	13/802,075	Mar 13, 2013	9,238,053	Jan 19, 2016
Australia	Issued	2010281436	July 27, 2010	2010281436	July 7, 2016
Brazil	Pending	BR122021007932-3	July 27, 2010		
Canada	Issued	2,769,347	July 27, 2010	2769347	Mar 29, 2022
China	Issued	201080042858.4	July 27, 2010	ZL 201080042858.4	Apr 17, 2018
Denmark	Issued	10806903.0	July 27, 2010	2459183	Oct 7, 2015
Germany	Issued	10806903.0	July 27, 2010	602010028120.5	Oct 7, 2015
European Patent Office	Issued	10806903.0	July 27, 2010	2459183	Oct 7, 2015
France	Issued	10806903.0	July 27, 2010	2459183	Oct 7, 2015
Hong Kong	Issued	12110525.9	July 27, 2010	1169804	Sep 30, 2016
India	Issued	1614/CHENP/2012	July 27, 2010	413642	Dec 5, 2022
Mexico	Issued	MX/a/2012/001139	July 27, 2010	329837	May 4, 2015
New Zealand	Issued	597763	July 27, 2010	597763	Oct 29, 2014
Singapore	Issued	10201406930U	July 27, 2010	10201406930U	Oct 22, 2020
South Africa	Issued	201200584	July 27, 2010	201200584	Mar 26, 2014
Switzerland	Issued	10806903.0	July 27, 2010	2459183	Oct 7, 2015
United Kingdom	Issued	10806903.0	July 27, 2010	2459183	Oct 7, 2015
PCT	Nationalized	PCT/US2010/043430	July 27, 2010		